{
  "abstract": "We propose a two-stage production method to overcome existing supply-constraints for the alpha-emitter $^{149\\mathrm{g}}$Tb, a promising candidate for Targeted Alpha Therapy (TAT) with no existing globally scalable production pathway. Although awaiting experimental measurement of the $^{150}$Gd(p,2n)$^{149\\mathrm{g}}$Tb cross section, the proposed method could produce $^{149\\mathrm{g}}$Tb at clinical scale and beyond on readily available proton cyclotrons, enabled by production of the extinct but long-lived isotope $^{150}$Gd, a pure alpha emitter with a 1.79 million year half-life. Stage one generates $^{150}$Gd feedstock by irradiating natural Eu or enriched $^{151}$Eu with $\\gtrsim$10 MeV protons, neutrons or photons. Stage two produces $^{149\\mathrm{g}}$Tb from fabricated $^{150}$Gd targets by driving the $^{150}$Gd(p,2n)$^{149\\mathrm{g}}$Tb reaction with $\\gtrsim$14 MeV protons, accessible on over 700 reported cyclotrons worldwide. Fast fusion neutrons appear to offer the most scalable pathway for $^{150}$Gd production: even with a large $^{149 \\mathrm{g}}$Tb dose size of 1 GBq and 40 million administered doses/yr, we estimate this would require neutrons produced by only 6.8 megawatts of steady-state deuterium-tritium power to produce the required $^{150}$Gd, far below expected capacity in the next decade. The route described here, if validated, would enable $^{149\\mathrm{g}}$Tb supply at the scale needed to support clinical development of $^{149\\mathrm{g}}$Tb-based TAT.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": "2609.25554",
  "author_total": 2,
  "authors": [
    {
      "name": "J. F. Parisi"
    },
    {
      "name": "A. Rutkowski"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c6s3tasdhh3np.bib",
  "cited_by": 0,
  "doi": "10.48550/arxiv.2609.25554",
  "fulltext_url": null,
  "id": "c6s3tasdhh3np",
  "issns": [],
  "landing_url": "https://arxiv.org/abs/2609.25554",
  "language": null,
  "licence": "LicenseRef-arXiv-nonexclusive-1.0",
  "licence_label": "arXiv licence",
  "licence_source": "article",
  "licence_url": "http://arxiv.org/licenses/nonexclusive-distrib/1.0/",
  "metadata_licence": "CC0-1.0",
  "native_subjects": [
    [
      "arxiv",
      "nucl-ex"
    ],
    [
      "arxiv",
      "physics.plasm-ph"
    ],
    [
      "openalex",
      "2741|Radiopharmaceutical Chemistry and Applications"
    ]
  ],
  "openalex": "W7214081751",
  "pdf_url": "https://arxiv.org/pdf/2609.25554",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-22",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/c6s3tasdhh3np.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:23:39Z",
      "native_id": "2609.25554",
      "source": "arxiv",
      "url": "https://arxiv.org/abs/2609.25554"
    }
  ],
  "subjects": [
    {
      "field": "physics",
      "origin": "arxiv:nucl-ex",
      "subfield": "nuclear"
    },
    {
      "field": "physics",
      "origin": "arxiv:physics.plasm-ph",
      "subfield": "plasma"
    }
  ],
  "title": "Scalable Terbium-149 Production from Highly Enriched Gadolinium-150 Targets",
  "title_text": "Scalable Terbium-149 Production from Highly Enriched Gadolinium-150 Targets",
  "type": "preprint",
  "updated_at": "2026-10-30T12:23:39Z",
  "url": "https://research.draconitic.com/paper/c6s3tasdhh3np",
  "venue": "arXiv",
  "versions": []
}